Results 21 to 30 of about 52,382 (294)

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. [PDF]

, 2019
PURPOSE: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.
Bohlius, Julia, Bohlke, Kari, Castelli, Roberto, Djulbegovic, Benjamin, Lazo-Langner, Alejandro, Lustberg, Maryam B, Martino, Massimo, Mountzios, Giannis, Peswani, Namrata, Porter, Laura, Tanaka, Tiffany N., Trifirò, Gianluca, Yang, Hushan   +12 more
core   +3 more sources

Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Haematologica, 2015
Although numerous recent publications have demonstrated interest in multiparameter flow cytometry in the investigation of myelodysplastic disorders, it is perceived by many laboratory hematologists as difficult and expensive, requiring a high level of ...
Valérie Bardet, Orianne Wagner-Ballon, Julien Guy, Céline Morvan, Camille Debord, Franck Trimoreau, Emmanuel Benayoun, Nicolas Chapuis, Nicolas Freynet, Cédric Rossi, Stéphanie Mathis, Marie-Pierre Gourin, Andréa Toma, Marie C. Béné, Jean Feuillard, Estelle Guérin   +15 more
doaj   +1 more source

Extramedullary Hematopoiesis in Myelodysplastic Syndromes: A Systematic Literature Review

Hemato, 2022
Extramedullary hematopoiesis is rarely seen in patients with myelodysplastic syndromes, and its clinical characterizations are not well-defined.
Chen Wang, Yiyun Shi
doaj   +1 more source

Myelodysplastic syndromes: Aspects of current medical care and economic considerations in Germany [PDF]

, 2008
Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases mainly affecting older people. The use of an increasing number of therapeutic options depends on a systematic risk stratification of the patients.
Berger, Karin, Gattermann, Norbert, Hofmann, Wolf-Karsten, Meeßen, Axel, Plesnila-Frank, Carlotta, Schmitz, Stephan, Schramm, Wolfgang, Tsamaloukas, Anton, Vollmer, Tanja, Wedding, Ulrich   +9 more
core   +1 more source

Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes

Haematologica, 2012
Background Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis. Survivin is a member of the inhibitor of apoptosis family and suppresses apoptosis.
Akira Yoshida, Kouichi Zokumasu, Yuji Wano, Takahiro Yamauchi, Shin Imamura, Kazutaka Takagi, Shinji Kishi, Yoshimasa Urasaki, Kaoru Tohyama, Takanori Ueda   +9 more
doaj   +1 more source

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else

Revista Brasileira de Hematologia e Hemoterapia, 2014
Although myelodysplastic syndromes have a clear definition in theory, the morphologic dysplasia associated with ineffective hematopoiesis may be subtle and difficult to recognize and can commonly be mimicked by systemic conditions, such as infections ...
Paula de Melo Campos, Fabiola Traina, Irene Lorand-Metze, Sara Teresinha Olalla Saad   +3 more
doaj   +1 more source

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax

Case Reports in Hematology, 2020
Myelodysplastic syndromes are characterized by ineffective hematopoiesis in one or more lineages of the bone marrow. They are a group of heterogeneous clonal stem cell malignancies with a high risk to progress to acute myeloid leukemia.
Waqas Jehangir, Alexander Karabachev, Taimoor Jahangir, Elvira Umyarova   +3 more
doaj   +1 more source

Chromosomal in situ suppression hybridization of immunologically classified mitotic cells in hematologic malignancies [PDF]

, 1992
Chromosomal in situ suppression (CISS) hybridization was performed with library DNA from sorted human chromosomes 8, 9, 15, 17, 21, and 22 on immunologically stained bone marrow cells of four patients with a hematologic neoplasm, including two patients ...
Arnoldus, Cremer, Cremer, Dauwerse, Edwards, Erber, Hopman, Johnson, Jotterand Bellomo, Knuutila, Knuutila, Larramendy, Larramendy, Lichter, Lichter, Marianne Tiainen, Martine Jotterand Bellomo, Patricia Emmerich, Perez Losada, Pinkel, Pinkel, Popp, Sakari Knuutila, Susanne Popp, Tapani Ruutu, Teerenhovi, Thomas Cremer, Valerie Parlier, Wessman, Willard   +29 more
core   +1 more source

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies

Haematologica, 2010
Background There is little published information on the everyday clinical management of myelodysplastic syndromes in real world practice.Design and Methods We conducted a cross-sectional study of all patients with myelodysplastic syndromes attending 74 ...
Charikleia Kelaidi, Aspasia Stamatoullas, Odile Beyne-Rauzy, Emmanuel Raffoux, Bruno Quesnel, Agnes Guerci, François Dreyfus, Sabine Brechignac, Christian Berthou, Thomas Prebet, Yosr Hicheri, Maya Hacini, Jacques Delaunay, Marie-Pierre Gourin, Jean-Marie Camo, Hacene Zerazhi, Anne-Laure Taksin, Laurence Legros, Bachra Choufi, Pierre Fenaux   +19 more
doaj   +1 more source